Literature DB >> 25639322

Pitfalls in the diagnosis and management of Cushing's syndrome.

Vivek Bansal1, Nadine El Asmar, Warren R Selman, Baha M Arafah.   

Abstract

Despite many recent advances, the management of patients with Cushing's disease continues to be challenging. Cushing's syndrome is a complex metabolic disorder that is a result of excess glucocorticoids. Excluding the exogenous causes, adrenocorticotropic hormone-secreting pituitary adenomas account for nearly 70% of all cases of Cushing's syndrome. The suspicion, diagnosis, and differential diagnosis require a logical systematic approach with attention paid to key details at each investigational step. A diagnosis of endogenous Cushing's syndrome is usually suspected in patients with clinical symptoms and confirmed by using multiple biochemical tests. Each of the biochemical tests used to establish the diagnosis has limitations that need to be considered for proper interpretation. Although some tests determine the total daily urinary excretion of cortisol, many others rely on measurements of serum cortisol at baseline and after stimulation (e.g., after corticotropin-releasing hormone) or suppression (e.g., dexamethasone) with agents that influence the hypothalamic-pituitary-adrenal axis. Other tests (e.g., measurements of late-night salivary cortisol concentration) rely on alterations in the diurnal rhythm of cortisol secretion. Because more than 90% of the cortisol in the circulation is protein bound, any alteration in the binding proteins (transcortin and albumin) will automatically influence the measured level and confound the interpretation of stimulation and suppression data, which are the basis for establishing the diagnosis of Cushing's syndrome. Although measuring late-night salivary cortisol seems to be an excellent initial test for hypercortisolism, it may be confounded by poor sampling methods and contamination. Measurements of 24-hour urinary free-cortisol excretion could be misleading in the presence of some pathological and physiological conditions. Dexamethasone suppression tests can be affected by illnesses that alter the absorption of the drug (e.g., malabsorption, celiac disease) and by the concurrent use of medications that interfere with its metabolism (e.g., inducers and inhibitors of the P450 enzyme system). In this review, the authors aim to review the pitfalls commonly encountered in the workup of patients suspected to have hypercortisolism. The optimal diagnosis and therapy for patients with Cushing's disease require the thorough and close coordination and involvement of all members of the management team.

Entities:  

Keywords:  ACTH = adrenocorticotropic hormone; CRH = corticotropin-releasing hormone; Cushing's syndrome; HPA = hypothalamic-pituitary-adrenal; HPLC = high-pressure liquid chromatography; IPSS = inferior petrosal sinus sampling; diagnostic pitfalls; hypercortisolism

Mesh:

Substances:

Year:  2015        PMID: 25639322     DOI: 10.3171/2014.11.FOCUS14704

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  15 in total

Review 1.  CT and MRI of adrenal gland pathologies.

Authors:  Fuqin Wang; Junwei Liu; Ruoxi Zhang; Yonghua Bai; Cailin Li; Bangguo Li; Heng Liu; Tijiang Zhang
Journal:  Quant Imaging Med Surg       Date:  2018-09

2.  Serum but not salivary cortisol levels are influenced by daily glycemic oscillations in type 2 diabetes.

Authors:  Giuseppe Bellastella; Maria Ida Maiorino; Annamaria De Bellis; Maria Teresa Vietri; Carmela Mosca; Lorenzo Scappaticcio; Daniela Pasquali; Katherine Esposito; Dario Giugliano
Journal:  Endocrine       Date:  2015-10-28       Impact factor: 3.633

3.  Consensus-driven in-hospital cortisol assessment after ACTH-secreting pituitary adenoma resection.

Authors:  Yana Stolyarov; James Mirocha; Adam N Mamelak; Anat Ben-Shlomo
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

4.  Perioperative hypothalamic pituitary adrenal function in patients with silent corticotroph adenomas.

Authors:  Abdelle F Cheres; Nadine ElAsmar; Aman Rajpal; Warren R Selman; Baha M Arafah
Journal:  Pituitary       Date:  2017-08       Impact factor: 4.107

Review 5.  Two types of ectopic Cushing syndrome or a continuum? Review.

Authors:  Marta Araujo Castro; Mónica Marazuela Azpiroz
Journal:  Pituitary       Date:  2018-10       Impact factor: 4.107

Review 6.  The Bidirectional Relationship between Tuberculosis and Diabetes.

Authors:  Ernest Yorke; Yacoba Atiase; Josephine Akpalu; Osei Sarfo-Kantanka; Vincent Boima; Ida Dzifa Dey
Journal:  Tuberc Res Treat       Date:  2017-11-12

Review 7.  Screening for Cushing Syndrome at the Primary Care Level: What Every General Practitioner Must Know.

Authors:  Ernest Yorke; Yacoba Atiase; Josephine Akpalu; Osei Sarfo-Kantanka
Journal:  Int J Endocrinol       Date:  2017-07-27       Impact factor: 3.257

Review 8.  Adrenal Hypercortisolism: A Closer Look at Screening, Diagnosis, and Important Considerations of Different Testing Modalities.

Authors:  Iacopo Chiodini; Arelys Ramos-Rivera; Alan O Marcus; Hanford Yau
Journal:  J Endocr Soc       Date:  2019-04-11

9.  The Role of Isotretinoin Therapy for Cushing's Disease: Results of a Prospective Study.

Authors:  Lucio Vilar; José Luciano Albuquerque; Ruy Lyra; Erik Trovão Diniz; Frederico Rangel Filho; Patrícia Gadelha; Ana Carolina Thé; George Robson Ibiapina; Barbara Sales Gomes; Vera Santos; Maíra Melo da Fonseca; Karoline Frasão Viana; Isis Gabriella Lopes; Douglas Araújo; Luciana Naves
Journal:  Int J Endocrinol       Date:  2016-02-29       Impact factor: 3.257

10.  Accuracy of the dexamethasone suppression test for the prediction of autonomous cortisol secretion-related comorbidities in adrenal incidentalomas.

Authors:  Marta Araujo-Castro; Paola Parra Ramírez; Cristina Robles Lázaro; Rogelio García Centeno; Paola Gracia Gimeno; Mariana Tomé Fernández-Ladreda; Miguel Antonio Sampedro Núñez; Mónica Marazuela; Héctor F Escobar-Morreale; Pablo Valderrabano
Journal:  Hormones (Athens)       Date:  2021-07-17       Impact factor: 2.885

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.